Interleukin-12 as an adjuvant for paramyxoviridae vaccines

Abstract

A method is disclosed of reducing viral replication of a virus of the paramyxoviridae family in a host, comprising administering to the host an antigen of the virus in combination with an effective adjuvant amount of interleukin-12 (IL-12). Human viruses of the paramyxoviridae family include paramyxoviruses (e.g., parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3 and parainfluenza virus 4), morbilliviruses (e.g., measles virus) and pneumoviruses (e.g., respiratory syncytial virus); other non-human viruses of the paramyxoviridae family include canine distemper virus, bovine respiratory syncytial virus, Newcastle disease virus and rhinderpest virus. A composition is also disclosed comprising a mixture of an antigen of a virus of the Paramyxoviridae family and an effective adjuvant amount of interleukin-12 (IL-12).

1 - 18 . (canceled)  
     
     
         19 . A composition for reducing replication of a virus of the  Paramyxoviridae  family in a host, comprising a mixture of an antigen of the virus and an effective adjuvant amount of interleukin-12.  
     
     
         20 . A composition of  claim 19  wherein the virus of the  Paramyxoviridae  family is selected from the group consisting of: parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, mumps virus, measles virus, respiratory syncytial virus, canine distemper virus, bovine respiratory syncytial virus, Newcastle disease virus and rhinderpest virus.  
     
     
         21 . A composition of  claim 19  wherein the antigen is selected from the group consisting of: the fusion glycoprotein, the hemagglutinin-neuraminidase, the G glycoprotein, and an inactivated  Paramyxoviridae.    
     
     
         22 . A composition of  claim 19  wherein the composition optionally contains one or more of other adjuvants, pharmaceutically acceptable surfactants, excipients, carriers, diluents, vehicles, sweetening agents, flavoring agents, and coloring agents.  
     
     
         23 . A composition of  claim 19  wherein the antigen is present as a polynucleotide and is expressed in vivo.  
     
     
         24 . A composition of  claim 19  wherein the virus of the  Paramyxoviridae  family is respiratory syncytial virus.  
     
     
         25 . A composition of  claim 24  wherein the antigen is selected from the group consisting of: the fusion glycoprotein, the G glycoprotein, and an inactivated respiratory syncytial virus.  
     
     
         26 . A composition of  claim 24  wherein the composition optionally contains one or more of other adjuvants, pharmaceutically acceptable surfactants, excipients, carriers, diluents, vehicles, sweetening agents, flavoring agents, and coloring agents.  
     
     
         27 . A composition of  claim 24  wherein the antigen is present as a polynucleotide and is expressed in vivo.